Gene therapy for retinal degeneration & genetic hearing loss

ICM Co., Ltd. is a South Korean biotechnology company established in 2012 as a subsidiary of Yonsei Technology Holdings, specializing in the development of AAV-based gene therapies. The company focuses on creating first-in-class treatments for incurable degenerative and genetic diseases, such as osteoarthritis and age-related macular degeneration. ICM utilizes its proprietary Baculovirus Dual Vector Method (BDVM) for the manufacturing of recombinant AAV therapeutic vectors. This production system is designed to provide high-yield, reproducible results while reducing the risks of impurities associated with traditional HEK293 cell-based transfection methods, as it avoids materials originated from human cells and bacteria in the final production stages.

By delivering therapeutic genes to target tissues, ICM’s pipeline aims to restore lost cellular functions caused by aging, inflammation, oxidative stress, and inborn genetic mutations. The company’s lead candidate, ICM-203, is currently undergoing clinical development for osteoarthritis, with ongoing trials in Australia and approval for an FDA Investigational New Drug application. Through these efforts, ICM seeks to address significant unmet medical needs and improve quality of life for patients suffering from currently untreatable degenerative conditions. The firm maintains an active R&D infrastructure, including a certified corporate R&D center established in 2015, and has secured various funding and industry recognitions to advance its therapeutic portfolio globally.